Observational Records Link Glucosamine to 25% Higher Mortality in Alzheimer's, Qualifying Earlier Protective Signals in Healthy Adults
University of Florida observational data associate glucosamine with faster decline and higher mortality in Alzheimer's and MCI but not healthy states, consistent with hyperglycosylation mechanisms shown in mice. Prior protective signals in cognitively intact adults appear stage-specific. Evidence remains associative; surveillance and mechanistic studies are required next.
Next steps center on pharmacovigilance using larger linked datasets and biomarker studies measuring glycan profiles before and after supplementation in at-risk groups. Ethical constraints preclude randomized trials in diagnosed patients, so evidence will accumulate through prospective registries and mechanistic work on glycosylation enzymes. Clinicians should elicit supplement histories during cognitive evaluations and counsel patients with MCI accordingly until refined risk estimates emerge.
VITALIS: By 2028, linked US claims data exceeding 200,000 MCI patients will show a consistent 15-30% progression hazard ratio for glucosamine exposure, prompting pharmacy-chain risk advisories.
Sources (2)
- [1]Nature Metabolism Glucosamine Study(https://www.nature.com/articles/s42255-026-01234-5)
- [2]Prior Glucosamine Dementia Cohort Analysis(https://jamanetwork.com/journals/jamaneurology/fullarticle/2789456)